Matheus Leonardo Dallaqua Silva1, Alessandra Sussulini 1
Psychedelic compounds such as psilocin and psilocybin have drawn attention due to their therapeutic potential in neuropsychiatric disorders, particularly in treatment-resistant depression, chemical dependency, and more recently, in neurodegenerative diseases such as Alzheimer’s disease. However, the metabolic pathways of these compounds remain poorly understood, highlighting the need for further investigation to ensure their safe application in clinical settings.
This study aims to address this gap in the metabolic understanding of psilocin and psilocybin by conducting detailed comparative analyses of their metabolism using SH-SY5Y cell line models. For this purpose, Liquid Chromatography (LC) coupled with Mass Spectrometry (MS) will be employed. By investigating how these compounds interact with cellular signaling and metabolic pathways, the study seeks to identify specific biomarkers and response patterns that may clarify both the therapeutic efficacy and potential adverse effects of psilocin and psilocybin.
Preliminary tests: Although no results are available yet, the cellular model has already been successfully established, and the differentiation protocol is currently under testing.
Agradecimentos: I gratefully acknowledge the research funding agencies (FAPESP, CAPES, and CNPq) and my laboratory colleagues.